Allergy Therapeutics (LSE:AGY) Total Current Assets: £36.25 Mil (As of Dec. 2025)


What is Allergy Therapeutics Total Current Assets?

Allergy Therapeutics LSE:AGY +0.30% Total Current Assets is £36.25 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Allergy Therapeutics's total current assets for the quarter that ended in Dec. 2025 was £36.25 Mil.

Allergy Therapeutics  (LSE:AGY) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Allergy Therapeutics's Liquidation Value for the quarter that ended in Dec. 2025 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=10.084-66.755+0.75 * 10.981+0.5 * 13.786
=-41.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allergy Therapeutics Total Current Assets Related Terms

Allergy Therapeutics Total Current Assets Historical Data

* Premium members only.

The historical data trend for Allergy Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allergy Therapeutics Total Current Assets Chart

Allergy Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.86 42.39 33.53 33.48 34.68

Allergy Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.35 33.48 42.17 34.68 36.25

Allergy Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Allergy Therapeutics's Total Current Assets for the fiscal year that ended in Jun. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=12.59+5.385+13.915+2.787
=34.68

Allergy Therapeutics's Total Current Assets for the quarter that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=10.084+10.981+13.786+1.4
=36.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of £36.25 Mil mean?
Allergy Therapeutics (LSE:AGY) has a Total Current Assets of £36.25 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Allergy Therapeutics and its competitors.
Is Allergy Therapeutics' Total Current Assets too high?
Allergy Therapeutics' current Total Current Assets is £36.25 Mil.
How does Allergy Therapeutics' Total Current Assets compare to ZTS and UTHR?
Allergy Therapeutics' Total Current Assets of £36.25 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Drug Manufacturers company?
A good Total Current Assets depends on the Drug Manufacturers industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Allergy Therapeutics and its competitors. Allergy Therapeutics's current Total Current Assets is £36.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (LSE:AGY) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.03, compared to a current price of £0.07 — trading 124% above its estimated fair value. The current Total Current Assets is £36.25 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Allergy Therapeutics (LSE:AGY), the current Total Current Assets is £36.25 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allergy Therapeutics Business Description

Other Exchanges AGYTF:USAHHU:Germany
Address Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).